{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-086793","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.614361+00:00","generated_at":"2026-05-15T22:15:56.509212+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission","bullets":["Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.","Briefing book argues ALLELE study was adequate; includes updated efficacy data and European post-marketing data.","FDA Complete Response Letter was issued January 9, 2026; meeting seeks path forward for EBV+ PTLD therapy.","CEO Cokey Nguyen cites urgent unmet need expressed by PTLD community and physician advocates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-086793","json":"https://secwatch.observer/filing/0001193125-26-086793.json","markdown":"https://secwatch.observer/filing/0001193125-26-086793.md","text":"https://secwatch.observer/filing/0001193125-26-086793.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/0001193125-26-086793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/d121575d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:15:56.509212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}